Catecholamine prodrugs for use in the treatment of Parkinson's diseases

A compound according to formula (Id)

• wherein R1 and R2 are defined according to a) to c) below:
• a) R1 is selected from H, C1-C6 alkyl, benzyl and linear-C(O) C1-C6 alkyl and R2 is substituent (i) below;
• or
• b) R1 is substituent (i) below and R2 is selected from H, C1-C6 alkyl, benzyl and linear-C(O) C1-C6 alkyl;
• or
• c) R1 and R2 are both represented by substituent (i) below
• and
• wherein R3 is selected from H and —C(O) C1-C6 alkyl;
• and
• wherein * indicates the attachment point;
• and
• wherein the carbon atom at the attachment point on substituent (i) is in the S-configuration;
• with the proviso that when one of R1 or R2 is substituent (i) and R3 is H then the other of R1 or R2 cannot be linear-C(O) C1-C6 alkyl;
• or a pharmaceutically acceptable salt thereof.